navidea_cmyk

Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision...

Community-Bank-of-the-Bay

Bay Community Bancorp Earns $1.84 Million in Second Quarter 2022; Quarter is Highlighted by $119 Million Capital Raise and Core Loan Growth of $73.3 Million; Declares Quarterly Cash Dividend of $0.045 Per Share